Abstract. The fruit of Brucea javanica L. is a common herb used in Chinese medicine for the treatment of a variety of cancers. Our research group has previously identified bruceine D (BD), a quassinoid found abundantly in B. javanica, to have potent cytotoxic effect on a number of pancreatic cancer cell lines, including Panc-1, SW1990 and Capan-1 cells. In the present study, we showed that BD was also able to inhibit the growth of the Capan-2 human pancreatic adenocarcinoma cell line, but it exerted only modest cytotoxicity on the WRL68 human hepatocyte cell line and a human pancreatic progenitor cell line. The antiproliferative effects of BD were comparable to those exhibited by camptothecin and gemcitabine in our culture system. We found a dose-dependent decrease of the mitochondrial membrane potential in BD-treated Capan-2 cells as measured by the JC-1 assay. BD exposure was able to attenuate the expression of Bcl-2 protein in Capan-2 cells as detected by western blot analysis. In addition, the expression of both caspase 9 and caspase 3 in BD-treated Capan-2 cells was significantly accentuated. Moreover, BD was capable of inducing the fragmentation of genomic DNA in Capan-2 cells as evidenced by Hoechst staining. Cell cycle analysis demonstrated that BD could increase the percentage of Capan-2 cells in the subG 1 phase in a dose-related manner. An increase in the apoptosis of Capan-2 cells was also observed by Annexin V and PI staining. These results unequivocally indicate that BD induces cytotoxicity in Capan-2 cells via the induction of cellular apoptosis involving the mitochondrial pathway.
IntroductionHuman pancreatic cancer is a gastrointestinal malignancy with extremely poor prognosis owing to a lack of early clinical diagnosis and its intrinsic resistance to radiotherapy and chemotherapy (1,2). According to the Hong Kong Cancer Registry in 2009 pancreatic cancer was the 8th and 6th major cause of cancer-related deaths in males and females, respectively. As for the management of pancreatic cancer, surgical resection remains the only potentially curative treatment of pancreatic cancer. However, only 5-25% of the patients diagnosed with pancreatic cancer were operable, and chemotherapy thus remains the mainstay of palliative management for the locally advanced and metastatic stage of this cancer. The median disease-free survival following complete resection of the pancreatic tumor and adjuvant chemotherapy with the first line chemotherapeutic agent gemcitabine is 13.4 and 6.9 months, respectively (3-6). Although camptothecin has a positive effect on arresting pancreatic tumor growth, many unwanted sideeffects limit its clinical application (5,7). All these dismal data highlight an urgent need for new therapeutic agents that could produce better clinical outcomes for this deadly disease.Our previous studies have shown that the fruit of Brucea javanica L., a Chinese medicinal plant commonly used for cancer treatment, has potent in vitro anti-pancreatic cancer activity (8). Furthermore, bruceine D (BD), a qu...